HR 5573 114th Congress House Health Drug safety, medical device, and laboratory regulation Licensing and registrations Marketing and advertising

PRICED Act

Introduced: June 23, 2016 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jun 23, 2016

Referred to the House Committee on Energy and Commerce.

Jun 23, 2016

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

What's happening now June 23, 2016

Referred to the House Committee on Energy and Commerce.

Related & companion bills 1

Bill text 1 version